(Total Views: 418)
Posted On: 06/06/2019 6:03:42 PM
Post# of 149028
From what I read doing my original DD, leronlimab partially blocked the CCR5 receptor. I've being trying to find out for weeks if leronlimab used the same molecular uptake points as RANTES (responsible for metastasis). If it did this would prove out the mechanism of action in metastatic cancer.
Sometimes you need the wayback machine. In a paper from 2001 it looks like leronlimab do use the same uptake and thus leronlimab will block RANTES.
https://www.ncbi.nlm.nih.gov/pubmed/11134270
Sometimes you need the wayback machine. In a paper from 2001 it looks like leronlimab do use the same uptake and thus leronlimab will block RANTES.
https://www.ncbi.nlm.nih.gov/pubmed/11134270
(0)
(0)Scroll down for more posts ▼
